A Tiny Stamp for a Giant Problem: Microneedles Take on Peanut Allergy

ATLANTA, GA – June 02, 2026 – In the high-stakes world of biotechnology, where innovation often targets the most complex diseases, a deceptively simple device is generating significant buzz. Atlanta-based Moonlight Therapeutics has officially begun human trials for MOON101, an investigational therapy for peanut allergy delivered not by a pill or a syringe, but by a small, minimally invasive microneedle skin stamp. The initiation of the Phase I clinical trial, dubbed SURVEYOR, marks a critical pivot from promising lab research to human application, offering a new ray of hope for the millions living under the constant threat of a severe allergic reaction.

This development couldn't be more timely. The landscape of food allergy treatment is in a state of flux, defined by both groundbreaking progress and notable setbacks. MOON101 enters a market desperately seeking safer, more convenient, and more effective solutions, and its unique technological approach could represent a fundamental shift in how we manage life-threatening allergies.

The Shifting Sands of Allergy Treatment

For decades, the standard of care for peanut allergy has been a defensive strategy: strict avoidance and an emergency epinephrine auto-injector at the ready. This paradigm began to shift in 2020 with the FDA approval of Palforzia, the first oral immunotherapy (OIT) designed to desensitize children to peanuts. While a landmark achievement, the treatment required a demanding regimen of daily dosing and carried the risk of triggering allergic reactions, including anaphylaxis. In a move that underscored these challenges, Palforzia's current owner announced the product will be discontinued by mid-2026, creating a significant vacuum in the market.

More recently, in early 2024, the FDA approved the biologic drug Xolair (omalizumab) for patients with one or more food allergies. By reducing the IgE antibodies that drive allergic reactions, it helps protect against accidental exposure. Yet, it requires regular injections and does not eliminate the need for allergen avoidance. Meanwhile, DBV Technologies continues its quest for approval of its Viaskin Peanut patch, an epicutaneous therapy that delivers peanut protein through the skin, with plans for another FDA submission in 2026.

Against this backdrop of incremental gains and persistent challenges, the need for a treatment that is both effective and patient-friendly has never been more acute. The ideal therapy would not only reduce the risk of severe reactions but would do so with a lower burden on patients and families, minimizing side effects and fitting more seamlessly into daily life. This is the precise niche Moonlight Therapeutics aims to fill.

A Prickly Solution: The Science of Intradermal Immunotherapy

The core innovation behind MOON101 lies in its delivery system. The proprietary microneedle stamp is designed to painlessly penetrate the skin's outermost layer, delivering microgram doses of peanut extract directly into the epidermis and superficial dermis. This area, often overlooked, is a strategic goldmine for immunotherapy.

The skin is the body's largest immune organ, densely populated with highly specialized antigen-presenting cells (APCs) like Langerhans cells. These cells act as sentinels, capturing foreign substances and presenting them to the immune system to orchestrate a response. By delivering the allergen directly to this immune-rich environment, intradermal therapy aims to program the body for tolerance, rather than an allergic attack, with potentially greater efficiency and a fraction of the allergen dose required for oral therapies.

This targeted approach offers several potential advantages. By concentrating the therapy in the skin and limiting its spread into the bloodstream, microneedle delivery may significantly reduce the risk of systemic side effects and anaphylaxis that can complicate OIT. Furthermore, the simplicity of a stamp applied for just a few minutes opens the door to a low-burden treatment that could one day be administered at home, a game-changer for patient adherence and quality of life.

“There remains a significant unmet need for safe, convenient, and accessible treatment options for peanut allergy,” said Brian P. Vickery, M.D., Professor of Pediatrics at Emory University and protocol chair for the study. “We are encouraged by the preclinical data supporting this platform and look forward to evaluating the safety and tolerability of MOON101 in peanut-allergic individuals.”

Moonlight's Moment: The SURVEYOR Trial Takes Flight

The journey from a laboratory concept to a human clinical trial is a gauntlet that few biotech startups successfully navigate. For Moonlight Therapeutics, the initiation of the SURVEYOR trial is a testament to the strength of its preclinical science, validated by a multi-million-dollar grant from the National Institute of Allergy and Infectious Diseases (NIAID) to support the study.

“This is an exciting milestone for Moonlight Therapeutics and for the millions of families impacted by peanut allergy,” said Samir Patel, Ph.D., co-founder and Chief Executive Officer of the company. “Initiating SURVEYOR marks the transition of MOON101 from promising preclinical research into human studies. Our goal is to develop a patient-friendly therapy capable of safely modulating the immune response to peanuts and ultimately reducing the risk of severe allergic reactions.”

The Phase I trial is an open-label, ascending-dose study designed primarily to assess the safety and tolerability of MOON101. It will enroll approximately 40 participants, sequentially including adults, adolescents, and children as young as four. Over five treatment visits, investigators will carefully administer escalating doses and monitor for adverse events while also gathering preliminary data on immunologic responses.

This first step is crucial. The data generated will inform the dosing strategy for future, larger trials and provide the first human evidence of the platform's potential. By collaborating with leading academic food allergy centers and the clinical research organization Dr. Vince Clinical Research, Moonlight is building a foundation of rigorous, high-quality data to guide the therapy's continued development. For the families navigating the daily anxiety of a food allergy, the progress of this trial represents a tangible step toward a more secure future.